Protein kinase C isozymes as therapeutic targets for treatment of human cancers

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

PKC isozymes play specific, non-redundant functional roles in numerous cellular processes, including proliferation, differentiation, cellular invasion and apoptosis. We have determined that PKCβII and PKCι are both critical pro-carcinogenic genes involved in multiple human cancers. PKCι (PRKCI) is a bonafide human oncogene, the first PKC isozyme that can be so classified. Both PKCβII and PKCι are legitimate therapeutic targets to which novel targeted therapy has been successfully developed and is being evaluated clinically.

Original languageEnglish (US)
Pages (from-to)166-178
Number of pages13
JournalAdvances in Enzyme Regulation
Volume48
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Protein Kinase C
Isoenzymes
Oncogenes
Neoplasms
Genes
Cell Proliferation
Apoptosis
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Protein kinase C isozymes as therapeutic targets for treatment of human cancers. / Fields, Alan P; Murray, Nicole R.

In: Advances in Enzyme Regulation, Vol. 48, No. 1, 2008, p. 166-178.

Research output: Contribution to journalArticle

@article{d4de12f02c4c403e91aad55028295748,
title = "Protein kinase C isozymes as therapeutic targets for treatment of human cancers",
abstract = "PKC isozymes play specific, non-redundant functional roles in numerous cellular processes, including proliferation, differentiation, cellular invasion and apoptosis. We have determined that PKCβII and PKCι are both critical pro-carcinogenic genes involved in multiple human cancers. PKCι (PRKCI) is a bonafide human oncogene, the first PKC isozyme that can be so classified. Both PKCβII and PKCι are legitimate therapeutic targets to which novel targeted therapy has been successfully developed and is being evaluated clinically.",
author = "Fields, {Alan P} and Murray, {Nicole R}",
year = "2008",
doi = "10.1016/j.advenzreg.2007.11.014",
language = "English (US)",
volume = "48",
pages = "166--178",
journal = "Advances in Biological Regulation",
issn = "2212-4926",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Protein kinase C isozymes as therapeutic targets for treatment of human cancers

AU - Fields, Alan P

AU - Murray, Nicole R

PY - 2008

Y1 - 2008

N2 - PKC isozymes play specific, non-redundant functional roles in numerous cellular processes, including proliferation, differentiation, cellular invasion and apoptosis. We have determined that PKCβII and PKCι are both critical pro-carcinogenic genes involved in multiple human cancers. PKCι (PRKCI) is a bonafide human oncogene, the first PKC isozyme that can be so classified. Both PKCβII and PKCι are legitimate therapeutic targets to which novel targeted therapy has been successfully developed and is being evaluated clinically.

AB - PKC isozymes play specific, non-redundant functional roles in numerous cellular processes, including proliferation, differentiation, cellular invasion and apoptosis. We have determined that PKCβII and PKCι are both critical pro-carcinogenic genes involved in multiple human cancers. PKCι (PRKCI) is a bonafide human oncogene, the first PKC isozyme that can be so classified. Both PKCβII and PKCι are legitimate therapeutic targets to which novel targeted therapy has been successfully developed and is being evaluated clinically.

UR - http://www.scopus.com/inward/record.url?scp=51349135500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349135500&partnerID=8YFLogxK

U2 - 10.1016/j.advenzreg.2007.11.014

DO - 10.1016/j.advenzreg.2007.11.014

M3 - Article

VL - 48

SP - 166

EP - 178

JO - Advances in Biological Regulation

JF - Advances in Biological Regulation

SN - 2212-4926

IS - 1

ER -